1. Home
  2. HIX vs SENS Comparison

HIX vs SENS Comparison

Compare HIX & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset High Income Fund II Inc.

HIX

Western Asset High Income Fund II Inc.

HOLD

Current Price

$3.95

Market Cap

356.7M

Sector

Finance

ML Signal

HOLD

Logo Senseonics Holdings Inc.

SENS

Senseonics Holdings Inc.

HOLD

Current Price

$5.66

Market Cap

301.2M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
HIX
SENS
Founded
1998
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Industrial Machinery/Components
Sector
Finance
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
356.7M
301.2M
IPO Year
1998
2014

Fundamental Metrics

Financial Performance
Metric
HIX
SENS
Price
$3.95
$5.66
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$18.38
AVG Volume (30 Days)
278.6K
867.1K
Earning Date
01-01-0001
05-08-2026
Dividend Yield
13.14%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$16,389,000.00
Revenue This Year
N/A
$74.15
Revenue Next Year
N/A
$58.60
P/E Ratio
N/A
N/A
Revenue Growth
N/A
19.85
52 Week Low
$3.75
$0.41
52 Week High
$4.39
$8.75

Technical Indicators

Market Signals
Indicator
HIX
SENS
Relative Strength Index (RSI) 49.23 40.65
Support Level $3.89 $5.40
Resistance Level $4.04 $5.94
Average True Range (ATR) 0.04 0.39
MACD 0.00 -0.13
Stochastic Oscillator 46.67 15.81

Price Performance

Historical Comparison
HIX
SENS

About HIX Western Asset High Income Fund II Inc.

Western Asset High Income Fund II Inc is a diversified closed-end management investment company. Its primary investment objective is to maximize current income by investing at least 80% of its net assets, plus any borrowings for investment purposes, in high-yield debt securities. As a secondary objective, the Fund seeks capital appreciation to the extent consistent with its objective of seeking to maximize current income.

About SENS Senseonics Holdings Inc.

Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.

Share on Social Networks: